Pioneering new therapies and treatments that shape the future of medicine.
With a reputation for creating new therapies and developing landmark treatments, our physicians tackle diverse clinical research areas, from cystic fibrosis to chronic Lyme disease, offering unique opportunities to engage in impactful clinical trials and contribute to the future of health care.
At Rutgers Cancer Institute of New Jersey—the state's only National Cancer Institute-designated Comprehensive Cancer Center—researchers are pushing the boundaries of medicine to target and beat cancer. Enrolling more than 3,000 patients each year, the network combines the strengths and skills of expert providers to improve the progress of research, education, and cancer prevention throughout the state.
An international clinical trial led by physician Jeffrey L. Carson, Distinguished Professor of Medicine, found that a liberal blood transfusion given to patients who have had a heart attack and have anemia may reduce the risk of a reoccurrence and improve survival rates.
A trial led by Keith Kaye, chief of the Division of Allergy, Immunology and Infectious Disease, found that the novel combination antibiotic sulbactam-durlobactam combats dangerous pneumonia at least as well as the best currently approved treatment.
The Pediatric Clinical Research Center was selected as a clinical trial site for the national research study by drug company Pfizer Inc. and French vaccine maker Valneva SE to evaluate the safety and efficacy of a vaccine for the prevention of Lyme disease in children over the age of 5.
The Clinical Trials Office provides support and centralized administrative functions for clinical researchers across Rutgers Health in their conduct of clinical trials and other prospective studies with the goal of improving the quality and efficiency of research.